Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL555101 | 1.00 | ACE (0.41) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL4270709 | 1.00 | ACE (0.41) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL23223889 | 0.94 | MEN1 (0.38) | ACE | |
| SCHEMBL157964 | 0.94 | MEN1 (0.38) | ACE | |
| SCHEMBL15904216 | 0.86 | — | — | |
| SCHEMBL16518728 | 0.85 | ACE (0.53) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL12658485 | 0.85 | ACE (0.53) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL12584754 | 0.81 | CNR1 (0.34) | — | |
| SCHEMBL14400492 | 0.81 | CNR1 (0.34) | — | |
| SCHEMBL8959051 | 0.81 | AR (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4382106-A1 | COMPOSITION FOR INHIBITING INFLAMMATION OR AGING OF STEM CELLS, AND METHOD FOR INHIBITING INFLAMMATION OR AGING BY USING SAME | MitoImmune Therapeutics Inc. (KR) | 2024-06-12 | — | — | EP | claimed |
| CN-118142070-A | Combined anti-aging method for improving skin quality and skin age | 厦门起点生物药业有限公司 | 2024-06-07 | — | — | CN | claimed |
| WO-2023182840-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION AND USE THEREOF | 주식회사 미토이뮨테라퓨틱스 | 2023-09-28 | — | — | WO | claimed |
| WO-2023146341-A1 | OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF | 주식회사 미토이뮨테라퓨틱스 | 2023-08-03 | — | — | WO | claimed |
| EP-3697501-B1 | HAIR TREATMENT COMPOSITION | UNILEVER IP HOLDINGS B V (NL) | 2023-06-21 | — | — | EP | claimed |
| CN-111683720-B | Hair treatment composition | 联合利华知识产权控股有限公司 | 2023-04-25 | — | — | CN | claimed |
| CN-113440435-B | Preparation method of skin anti-aging composition | 珀莱雅化妆品股份有限公司 | 2022-08-09 | — | — | CN | claimed |
| US-20130324555-A1 | Method of use of pharmaceutical formulations for the treatment of apicomplexan diseases in animals | WOOD RICHARD DELAREY (US) | 2013-12-05 | — | — | US | claimed |
| US-20130150416-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD D (US) | 2013-06-13 | — | — | US | claimed |
| US-20090239919-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY | 2009-09-24 | — | — | US | claimed |
| US-5770594-A | ANTICHOLESTEROL AGENTS, INHIBITORS OF CHOLESTEROL SYNTHESIS | PFIZER INC. (US) | 1998-06-23 | — | — | US | claimed |
| WO-1996020184-A1 | NAPHTHYL-BENZOXAZEPINES OR -BENZOTHIAZEPINES AS SQUALENE SYNTHETASE INHIBITORS | PFIZER INC. (US) | 1996-07-04 | — | — | WO | claimed |
| US-4638046-A | Retro-inverso C-terminal hexapeptide analogues of substance P | ENI-ENTE NAZIONALE IDROCARBURI (IT) | 1987-01-20 | — | — | US | claimed |
| EP-0161007-A2 | Retro - inverso C-Terminal hexapeptide analogues of substance P | ENI-Ente Nazionale Idrocarburi (IT) | 1985-11-13 | — | — | EP | claimed |
| EP-0082568-B1 | RETRO-INVERSO ANALOGUES OF C-TERMINAL PENTA AND HEXAPEPTIDES OF SUBSTANCE P. | ANIC S.p.A. (IT) | 1984-11-21 | — | — | EP | claimed |
| US-4439360-A | Retro-inverso analogues of C-terminal penta and hexapeptides of Substance P | ANIC S.P.A. (IT) | 1984-03-27 | — | — | US | claimed |
| EP-0082568-A2 | Retro-inverso analogues of C-terminal penta and hexapeptides of substance P. | ANIC S.p.A. (IT) | 1983-06-29 | — | — | EP | claimed |
| US-4321387-A | Process for the preparation of optically active nicotine analogs | PHILIP MORRIS, INCORPORATED (US) | 1982-03-23 | — | — | US | claimed |
| EP-4737449-A1 | P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-4321387-A | Process for the preparation of optically active nicotine analogs | PHILIP MORRIS, INCORPORATED (US) | 1982-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239919-A1 | Glutamate receptor modulators and therapeutic agents | GRM5, GRM1, GRIK5 | ACE 2281/4885REN 944/4885LMNA 4247/4885 |
| US-20130150416-A1 | Glutamate receptor modulators and therapeutic agents | GRM5, GRM1, GRIK5 | ACE 2375/4885REN 1833/4885LMNA 4491/4885 |
| US-20130324555-A1 | Method of use of pharmaceutical formulations for the treatment of apicomplexan diseases in animals | PIGS, ASAH2, ASAH1 | ACE 219/4885REN 1746/4885LMNA 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.